Literature DB >> 11285032

The presence of HPV DNA in cervical cancer: correlation with clinico-pathologic parameters and prognostic significance: 10 years experience at the Department of Obstetrics and Gynecology of the Mainz University.

H Pilch1, S Günzel, U Schäffer, B Tanner, P Brockerhoff, M Maeurer, M Höckel, G Hommel, P G Knapstein.   

Abstract

The objective of this study was to assess whether the presence of human papillomavirus (HPV) DNA and/or several genotypes of HPV DNA in cervical cancer are correlated with several clinicopathologic parameters of well-defined prognostic significance and whether virologic parameters are predictors of long-term survival in cancer patients. Two hundred twenty three cases of cervical cancer patients included in this retrospective study underwent follow-up evaluation. Survival and cause of death were examined for 204 (91.4%) patients, with a mean follow-up time of 4.4 years. HPV DNA was detected using the highly sensitive polymerase chain reaction (PCR) method followed by HPV DNA sequencing for HPV genotyping. These results were correlated with well-defined clinicopathologic parameters and survival data. HPV DNA was detected by PCR in 150 of 193 (73.4%) tissue specimens of cervical cancer patients. DNA sequence analysis revealed the presence of HPV 16 (n = 68, 45.3%), HPV 18 (n = 49, 32.6%) and rare HPV types (n = 33, 22.1%). HPV genotypes correlated significantly with histologic tumor types, node status, tumor oxygenation, blood vessel invasion, and lymph space involvement. The presence of HPV DNA in cervical cancer as well as the genotype of HPV 16 could also be confirmed as significant prognostic factors in the univariate Cox regression analysis (RR 2.856, P < 0.003 resp. RR 3.444, P < 0.0001). In the multivariate analysis, however, HPV DNA status failed to be of prognostic relevance. Exclusively HPV 16 appears to have an independent impact on the overall survival in cervical patients (RR 3.653, P < 0.002). We conclude that the detection of HPV 16 genotype may play an important adjunct role in assessing prognosis of cervical cancer patients. The clinical impact of the presence of HPV DNA in primary tumors of uterine cervix remains to be investigated in further studies, and the exact mechanisms by which HPV influences the prognosis of cervical cancer patients have to be defined.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11285032     DOI: 10.1046/j.1525-1438.2001.011001039.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  17 in total

Review 1.  Usefulness, methods and rationale of lymph nodes HPV-DNA investigation in estimating risk of early stage cervical cancer recurrence: a systematic literature review.

Authors:  Marco Noventa; Emanuele Ancona; Erich Cosmi; Carlo Saccardi; Pietro Litta; Donato D'Antona; Giovanni Battista Nardelli; Salvatore Gizzo
Journal:  Clin Exp Metastasis       Date:  2014-07-20       Impact factor: 5.150

2.  Comparison of real-time PCR signal-amplified in situ hybridization and conventional PCR for detection and quantification of human papillomavirus in archival cervical cancer tissue.

Authors:  Karin Biedermann; Nadia Dandachi; Maria Trattner; Georgia Vogl; Hildegard Doppelmayr; Elena Moré; Alfons Staudach; Otto Dietze; Cornelia Hauser-Kronberger
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

3.  Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands.

Authors:  S Bulk; J Berkhof; N W J Bulkmans; G D Zielinski; L Rozendaal; F J van Kemenade; P J F Snijders; C J L M Meijer
Journal:  Br J Cancer       Date:  2006-01-16       Impact factor: 7.640

4.  Prognostic implication of human papillomavirus types and species in cervical cancer patients undergoing primary treatment.

Authors:  Yat Ming Lau; Tak Hong Cheung; Winnie Yeo; Frankie Mo; Mei Yung Yu; Kun Min Lee; Wendy C S Ho; Apple C M Yeung; Priscilla T Y Law; Paul K S Chan
Journal:  PLoS One       Date:  2015-04-09       Impact factor: 3.240

5.  Human papillomavirus 18 as a poor prognostic factor in stage I-IIA cervical cancer following primary surgical treatment.

Authors:  Sun-Hye Yang; Su-Kyoung Kong; Seung-Ho Lee; So-Yi Lim; Chan-Yong Park
Journal:  Obstet Gynecol Sci       Date:  2014-11-20

Review 6.  HPV-Negative Cervical Cancer: A Narrative Review.

Authors:  Francesca Arezzo; Gennaro Cormio; Vera Loizzi; Gerardo Cazzato; Viviana Cataldo; Claudio Lombardi; Giuseppe Ingravallo; Leonardo Resta; Ettore Cicinelli
Journal:  Diagnostics (Basel)       Date:  2021-05-26

7.  Human papillomavirus types 16 and 18 and the prognosis of patients with stage I cervical cancer.

Authors:  Rossana de Araújo Catão Zampronha; Ruffo Freitas-Junior; Eddie Fernando Candido Murta; Márcia Antoniazi Michelin; Aline Almeida Barbaresco; Sheila Jorge Adad; Amaurillo Monteiro de Oliveira; Amanda B Rassi; Glória Jabur Bittar Oton
Journal:  Clinics (Sao Paulo)       Date:  2013-06       Impact factor: 2.365

8.  Expression of endoglin (CD105) in cervical cancer.

Authors:  H J Zijlmans; G J Fleuren; S Hazelbag; C F Sier; E J Dreef; G G Kenter; A Gorter
Journal:  Br J Cancer       Date:  2009-04-07       Impact factor: 7.640

9.  Incidence and survival rate of women with cervical cancer in the Greater Amsterdam area.

Authors:  S Bulk; O Visser; L Rozendaal; R H M Verheijen; C J L M Meijer
Journal:  Br J Cancer       Date:  2003-09-01       Impact factor: 7.640

10.  Genotype distribution and the relative risk factors for human papillomavirus in Urumqi, China.

Authors:  Zhifang Chen; Wei Meng; Rong DU; Yuejie Zhu; Yi Zhang; Yan Ding
Journal:  Exp Ther Med       Date:  2013-04-23       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.